Shanghai Pharmaceuticals' (SHA:601607, HKG:2607) unit, Nantong Changyou Pharmaceutical Technology, obtained approval from China's National Medical Products Administration to produce and market active pharmaceutical ingredient Vericiguat, according to a Shanghai Stock Exchange filing on Tuesday.
Vericiguat, which was originally developed by global pharmaceutical giant Merck Sharp & Dohme, is primarily indicated for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction, who have been stabilized following recent decompensated heart failure treated intravenously.
The Chinese pharma company invested 3.6 million yuan into the research and development of the API, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.